Vista Group Signs Aeon Entertainment, Japan’s Largest Cinema Chain
Vista Group International (NZX & ASX: VGL), the world’s leading provider of software solutions for the global film industry, has signed Aeon Entertainment Co Ltd (‘Aeon’), its first customer in Japan. Japan is one of the “top 5” film exhibition markets in the world by Box Office revenue.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180510006431/en/
Vista Group companies Vista Entertainment Solutions (‘Vista Cinema’) and Movio, will provide their respective cinema management and marketing data analytics software solutions to Aeon who operate 91 cinema sites throughout Japan comprising 774 screens.
The Agreement represents the realisation of a long-time goal for Vista Cinema, which has grown its global market share in the large circuit market to 38% over 20 years – but without the inclusion of Japan. The successful negotiation of the Agreement conducted over more than two years was achieved with the support of Vista’s in-market Business Partner VINX Corporation (‘VINX’), who will continue to work with Vista to execute the new Agreement including the deployment of Vista’s software and on-going support.
VINX has established a new cinema division with a focus on selling and supporting Japanese exhibitors. “Our partnership with Vista has initiated this new division within VINX and we’re very excited about the opportunity it represents. It is difficult to promote the foreign software package in Japan since we have developed customised systems for every customer. This partnership will allow us not only to expand our business together in Japan, but also it will help us enhance our global strategy. I am convinced that this Agreement will be the very first step of a great development and success for the Japanese cinema industry,” says Toshiya Fujita, President of VINX.
“With perseverance, determination and hard work and with the support of our partner VINX Corporation, we’ve finally realized our long-term goal of establishing the Vista brand in Japan,” said Kimbal Riley, Chief Executive of Vista Group. “With the implementation of Vista Cinema’s industry-leading cinema management software system and Movio’s unsurpassed marketing data insights and solutions, Aeon will absolutely enhance its leadership position. We are humble and grateful to partner with an organization with the reputation and standing that Aeon holds in Japan and our experience of Aeon is that they are a devoted and extraordinary team of cinema professionals.”
The combination of Vista Loyalty and Movio is the high-end solution choice for Aeon; the integration of the two products enhances the capture of data and marketing analytics and audience insights to enable the execution of optimally-targeted and integrated marketing campaigns. Aeon’s Loyalty program and Box Office return is expected to accelerate using Vista Loyalty and Movio together.
The roll-out of the Vista Cinema and Movio solutions for Aeon will be completed by February 2020.
About VINX Corporation
VINX Corp has been assisting the retailing IT revolution in Japan and
leading the standardization of retail systems as an expert in IT. VINX
keeps creating innovative products and services by taking advantage of
the know-how and long experience gained since 1991 in the retail
industry while also providing high quality IT services to domestic and
foreign countries, bringing together the power of the Fujisoft Group.
With more than 1,250 employees, VINX has developed ‘Cross-border IT
Solutions’ to solve overseas issues related to the IT of retailing
companies, boasting Japanese quality and providing network construction
among Japanese, Chinese and other Asian countries. To fully support the
‘China and ASEAN Strategy’ of the Japanese retailing industry, VINX has
established affiliates in China, Malaysia, and Vietnam, and has expanded
businesses in Asia to carry out offshore development in the field, and
equipment procurement in local areas.
About Vista Group International
Vista Group International (Vista Group) is a public company, listed on
both the New Zealand and Australian stock exchanges (NZX & ASX: VGL).
The Group provides software and additional technology solutions across
the global film industry. Cinema management software is provided by
Vista Cinema, the core business of the Group. Movio (authority in
moviegoer data analytics), Veezi (cloud-based SaaS software for the
Independent Cinema Market), movieXchange (connecting the movie industry
to simplify the promotion and sale of movie tickets), Maccs (film
distribution software), Numero (box office reporting software for film
distributors and cinemas), Cinema Intelligence (business intelligence
solutions), Powster (creative studio and marketing platform for movie
studios) and Flicks (moviegoer ‘go to’ portal for movie information)
provide an innovative range of complementary products across additional
film industry sectors, from production and distribution, to cinema
exhibition through to the moviegoer experience. Vista Group has offices
located in New Zealand (Auckland HQ), Sydney, Los Angeles, London,
Shanghai, Beijing, Mexico City, South Africa, the Netherlands and
About Vista Entertainment Solutions
Vista Entertainment Solutions Ltd (‘Vista Cinema’) is the world leader
in cinema management software solutions with installations in more than
90 countries around the world and an estimated 38% global market share
in the Large Cinema Circuit market. The Vista Cinema software product
line comprises multiple modules, integrated and scalable, suited to
cinema exhibitors operating 20+ screens and 100s of cinemas. Vista
Cinema is head-quartered in Auckland, New Zealand.
Movio, a company of Vista Group International (NZX & AXS: VGL), is the
global leader in marketing data analytics and campaign management
solutions, revolutionizing the way the film industry interacts with
moviegoers. With a global database of over 100 million moviegoers, 750
million behavioral and transactional records and more than 5000 movie
titles, Movio is the world’s most comprehensive source of moviegoer
data. The company’s investment in data science and machine learning has
produced market-leading technologies that redefine the possibilities of
movie marketing. Movio empowers marketers to connect moviegoers with
their ideal movie via online and offline channels, and link campaign
data with actual ticket purchases to close the loop and measure campaign
For Vista Group International/USA
+1 310 390 0101
For Vista Group International/NZ
Christine Fenby, +64 21 727 006
For VINX Corporation/Japan
Hitoshi Chiyoda, +81 3 5209 7359
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail firstname.lastname@example.org or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu